Cognivia

Belgium-based Cognivia provides platforms for clinical trial operators and sponsors to recruit, manage, and predict patient behaviors. The company offers two solutions, Placebell and Compl-AI. Placebell is a predictive platform that helps clinical trial sponsors predict recruited patients’ behavior toward placebos based on psychological profiles created of each trial participant. 

The platform allows for statistical analysis of recruited patients in order to reduce the risk of trial failure. Placebell, which is used specifically in Phase II and Phase III clinical trials, takes into account a patient’s psychological profile and uses machine learning to predict their individual responses to placebos. The company operates across 30+ countries, and its solutions have been used across 500+ investigator sites. 

In May 2023, the company launched a new patient recruitment and engagement solution, “Compl-AI.” The platform enables clinical trial sponsors to predict treatment non-adherence and dropout risks associated with potential patients through the use of machine-learning algorithms to analyze patient characteristics and traits. This product launch marked the company’s expansion of its product portfolio of patient management solutions. 

Funding and financials

In April 2024, the company Cognivia raised EUR 15.5 million (USD 16.5 million) in a funding round which saw participation from Vesalius Biocapital IV, Société Fédérale de Participations et d'Investissement (SFPIM) and Wallonie Entreprendre (WE). The raised funds were set aside to deploy the company’s AI and Machine Learning-based predictive clinical trial solutions that decode the relationship between patient traits and behaviors on a global scale.